Digital and computational pathology firm Proscia has announced that Virscio, a leading provider of translational research and development services, has deployed Concentriq for Research. The contract research organisation (CRO) is leveraging Proscia’s flagship software platform to provide faster, more informed drug safety insights, helping its sponsors to improve research and development efficiency.
Up to 90% of drug candidates fail during clinical trials, negatively impacting R&D efficiency, as measured by the number of new drugs approved relative to investment. Effective preclinical development hinges on accurate and high throughput evaluation of large volumes of pathology data to define the safety of a candidate before it can move on to human clinical trials. As such, Virscio recognised that optimising its pathology operations by adopting Concentriq for Research would enable its sponsors to more rapidly and confidently advance lead programmes and get therapeutic breakthroughs to patients sooner.
Concentriq is trusted by 14 of the top 20 pharmaceutical companies and leading CROs to drive quality and productivity gains across the R&D value chain. Virscio is leveraging the scalable, cloud-based platform to unify its teams and data across Good Laboratory Practice (GLP) and non-regulated studies, streamlining collaboration among its distributed scientists, sponsors, and external collaborators. The platform also offers world-class interoperability with leading image analysis and artificial intelligence (AI) applications, allowing Virscio’s scientists to unlock new insights that further inform decision making.
“Translating concept to clinical success requires innovative technology, and we’ve found this in Concentriq for Research,” said Matthew Lawrence, MD, PhD, Virscio’s Chief Executive Officer. “The platform enables us to see through our transformative approach to preclinical development and create added value for our teams and sponsors.”
“We are excited to welcome Virscio to the growing roster of organisations turning to Concentriq for Research to accelerate therapeutic innovation,” said David West, Proscia’s Chief Executive Officer. “Virscio is driving forward a new era of preclinical development, and we look forward to seeing the impact of digital pathology in addressing the critical challenge of R&D efficiency.”
